Identification of XZ8078 as a Dual-Target Degrader Targeting PARP1 and IKZF3 for Broad Spectrum Anticancer Treatment
may be a powerful therapeutic agent not only for treating PARPi-sensitive tumors but also PARPi-resistant tumors, even HR-proficient tumors.
Authors
- Ze‐Hong Miao (ORCID: https://orcid.org/0000-0002-0833-6583)
- X Wang
- Pingyuan Wang (ORCID: https://orcid.org/0009-0005-0368-5070)
- Xubin Bao
- Chang‐Yun Wang (ORCID: https://orcid.org/0000-0002-0236-1606)
- Xi Zhang (ORCID: https://orcid.org/0000-0002-4638-3997)
- Zhiqing Liu (ORCID: https://orcid.org/0000-0003-0266-6677)
- Jin-Xue He
- Yaoyao Li
- Jing He
Institutions
- Chinese Academy of Sciences (CN)
- Shanghai Institute of Materia Medica (CN)
- Qingdao National Laboratory for Marine Science and Technology (CN)
- Ministry of Education (KR)
- University of Chinese Academy of Sciences (CN)
- Ocean University of China (CN)
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2026-06-30
- DOI
- https://doi.org/10.1021/acs.jmedchem.6c00239
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00